nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Dyspnoea—Teniposide—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Confusional state—Fludarabine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Tobramycin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Tobramycin—Decreased appetite—Teniposide—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Tobramycin—Renal failure—Carmustine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Tobramycin—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Tobramycin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tobramycin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tobramycin—Apnoea—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tobramycin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tobramycin—Stomatitis—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Tobramycin—Rash—Mechlorethamine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Weight decreased—Vincristine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Tobramycin—Anorexia—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Tobramycin—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Tobramycin—Proteinuria—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Tobramycin—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Stomatitis—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Protein urine present—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Tobramycin—Bone disorder—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Renal failure—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Nausea—Mechlorethamine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Urticaria—Teniposide—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Tobramycin—Oliguria—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Tobramycin—Abdominal pain—Teniposide—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Body temperature increased—Teniposide—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Erythema—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Paraesthesia—Fludarabine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Tobramycin—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Tobramycin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Visual impairment—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Pain—Fludarabine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Tobramycin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Tobramycin—Urethral disorder—Vincristine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Tobramycin—Eye disorder—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Tobramycin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Tobramycin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Anaemia—Bleomycin—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Tobramycin—Asthenia—Teniposide—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Malaise—Bleomycin—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Pruritus—Teniposide—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Tobramycin—Leukopenia—Bleomycin—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Tobramycin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Tobramycin—Erythema—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Cough—Bleomycin—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Angiopathy—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Diarrhoea—Teniposide—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Myalgia—Bleomycin—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Chest pain—Bleomycin—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Back pain—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Discomfort—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Confusional state—Bleomycin—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Vision blurred—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Erythema—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Anaemia—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Back pain—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Tobramycin—Vomiting—Teniposide—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Tobramycin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Asthenia—Fludarabine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Rash—Teniposide—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Dermatitis—Teniposide—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tobramycin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Tobramycin—Headache—Teniposide—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Tobramycin—Pruritus—Fludarabine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Back pain—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Leukopenia—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Tobramycin—Anorexia—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Tobramycin—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Tobramycin—Anaemia—Vincristine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Tobramycin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Tobramycin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Nausea—Teniposide—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Vertigo—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Leukopenia—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tobramycin—Myalgia—Carmustine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tobramycin—Chest pain—Carmustine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tobramycin—Paraesthesia—Bleomycin—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Tobramycin—Malaise—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Renal failure acute—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Confusional state—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Tobramycin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Myalgia—Vincristine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Cough—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Vomiting—Fludarabine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Rash—Fludarabine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Dermatitis—Fludarabine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Pain—Bleomycin—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Tobramycin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Tobramycin—Headache—Fludarabine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Tobramycin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Lethargy—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Discomfort—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Anorexia—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Tobramycin—Nausea—Fludarabine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Urticaria—Bleomycin—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Anorexia—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Tobramycin—Body temperature increased—Bleomycin—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Paraesthesia—Carmustine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Dyspnoea—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Tobramycin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Decreased appetite—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Tobramycin—Paraesthesia—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Pain—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Tobramycin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Decreased appetite—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Asthenia—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Pain—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Asthma—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Pruritus—Bleomycin—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Eosinophilia—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Pain—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Tobramycin—Body temperature increased—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Abdominal pain—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Body temperature increased—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Abdominal pain—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Vomiting—Bleomycin—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Infestation—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Rash—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Dermatitis—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Asthenia—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Tobramycin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Asthenia—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Diarrhoea—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Nausea—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Tobramycin—Dizziness—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Diarrhoea—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Tobramycin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Vomiting—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Dizziness—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Rash—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Dermatitis—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Headache—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Vomiting—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Tobramycin—Rash—Vincristine—lymphatic system cancer	0.000998	0.000998	CcSEcCtD
Tobramycin—Dermatitis—Vincristine—lymphatic system cancer	0.000997	0.000997	CcSEcCtD
Tobramycin—Headache—Vincristine—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Tobramycin—Nausea—Carmustine—lymphatic system cancer	0.000985	0.000985	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Tobramycin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—lymphatic system cancer	0.000976	0.000976	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Tobramycin—Rash—Mitoxantrone—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Tobramycin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000971	0.000971	CcSEcCtD
Tobramycin—Headache—Mitoxantrone—lymphatic system cancer	0.000965	0.000965	CcSEcCtD
Tobramycin—Erythema—Methotrexate—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Tobramycin—Nausea—Vincristine—lymphatic system cancer	0.00094	0.00094	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Tobramycin—Nausea—Mitoxantrone—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Tobramycin—Back pain—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—lymphatic system cancer	0.000887	0.000887	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—lymphatic system cancer	0.00087	0.00087	CcSEcCtD
Tobramycin—Malaise—Methotrexate—lymphatic system cancer	0.000848	0.000848	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—lymphatic system cancer	0.000845	0.000845	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—lymphatic system cancer	0.000842	0.000842	CcSEcCtD
Tobramycin—Cough—Methotrexate—lymphatic system cancer	0.000821	0.000821	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—lymphatic system cancer	0.000801	0.000801	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—lymphatic system cancer	0.000801	0.000801	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—lymphatic system cancer	0.000774	0.000774	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000752	0.000752	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—lymphatic system cancer	0.000732	0.000732	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000689	0.000689	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000667	0.000667	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Tobramycin—Pain—Methotrexate—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000633	0.000633	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000628	0.000628	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—lymphatic system cancer	0.00061	0.00061	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000607	0.000607	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000607	0.000607	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000566	0.000566	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—lymphatic system cancer	0.000551	0.000551	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—lymphatic system cancer	0.000543	0.000543	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000525	0.000525	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—lymphatic system cancer	0.000488	0.000488	CcSEcCtD
Tobramycin—Rash—Methotrexate—lymphatic system cancer	0.000484	0.000484	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—lymphatic system cancer	0.000484	0.000484	CcSEcCtD
Tobramycin—Headache—Methotrexate—lymphatic system cancer	0.000481	0.000481	CcSEcCtD
Tobramycin—Nausea—Methotrexate—lymphatic system cancer	0.000456	0.000456	CcSEcCtD
